Oracle will integrate Nuance Communications' cloud-based medical speech recognition technology
Focused on improving productivity of clinical programs, reducing costs, and boosting study participant retention, health sciences organizations seek ways to accelerate and streamline clinical trial data collection and management. To support these objectives, Oracle will integrate Nuance Communications' (NASDAQ: NUAN) cloud-based medical speech recognition technology with Oracle Health Sciences e-clinical software.
News Facts
“Nuance’s medical speech and language understanding solutions allow people to stay productive by leveraging mobile devices, and cloud connectivity to communicate anywhere, anytime across devices and platforms,” said Peter Durlach, senior vice president marketing, Nuance Communications. “Embedding Nuance cloud-based medical speech solutions into Oracle’s clinical apps provides a more natural and efficient approach for clinical researchers and staff to deliver accurate information within their workflow.”
· “Clinical trial sponsors and contract research organizations around the world count on Oracle Health Sciences’ leading e-clinical solutions to help them automate and streamline their entire clinical development process,” said Nick Giannasi, vice president, Oracle Health Sciences. “We are committed to continued innovation, and working with Nuance will bring powerful voice-driven capabilities to our e-clinical solutions, making it easier and faster for investigators and study participants to capture and provide accurate clinical trial data.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.